Discovery and therapeutic potential of kinin receptor antagonists

Bibliography

• Stewart JM, Vavrek RJ. Bradykinin chemistry: agonists and antagonists. Adv Exp Med Biol 1983;156:585-9
   PubMedGoogle Scholar
• Vavrek RJ, Stewart JM. Development and modification of competitive antagonists of bradykinin. In Deber CM, Hruby VJ, Kopple DK (Editors). Peptides, Structure and Function. Proc 9h Am Pep Symp. Pierce Chem Co. 1985:655-58
   Google Scholar
• Werle E, Berek U. Zur kenntnis das kallikreins. Angew Chem 1948;60A:53
   Google Scholar
• Frey EK, Kraut H. Ein neues kreislaufhormon und seine wirkung. Arch Exp Pathol Pharmakol 1928;133:1-56
   Google Scholar
• Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function and association to disease. Endocr Rev 2001;22:184-204
   PubMed Web of Science ®Google Scholar
• Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004;41:265-312
   PubMed Web of Science ®Google Scholar
• Figueroa CD, Ehrenfeld P, Bhoola KD. Kinin receptors as targets for cancer therapy. Expert Opin Ther Targets 2012;16:299-312
   PubMed Web of Science ®Google Scholar
• Rocha e Silva M, Beraldo WT, Rosenfeld G. Bradykinin hypotensive and smooth muscle stimulating factor released from plasma globulins by snake venoms and trypsin. Am J Physiol 1949;156:261-71
   PubMed Web of Science ®Google Scholar
• Elliott DF, Lewis GP, Horton EW. The structure of bradykinin –a plasma kinin from ox blood. Biochem Biophys Res Commun 1960;3:87-91
   Web of Science ®Google Scholar
• Boissonnas RA, Guttmann S, Jaquenoud PA, Synthesis and biological activity of peptides related to bradykinin. Experientia 1960;16:326
   PubMedGoogle Scholar
• Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol Rev 1992;44:1-80
   PubMed Web of Science ®Google Scholar
• Leeb-Lundberg FLM, Marceau F, Müller-Esterl W, International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77
   PubMed Web of Science ®Google Scholar
• Regoli D, Barabé J, Park WK. Receptors for bradykinin in rabbit aorta. Can J Physiol Pharmacol 1977;55:855-67
   PubMed Web of Science ®Google Scholar
• Regoli D, Marceau F, Barabé J. De novo formation of vascular receptors for bradykinin. Can J Physiol Pharmacol 1978;5:674-7
   Google Scholar
• Drouin JN, Gaudreau P, St-Pierre S, Regoli D. Biological activities of kinins modified at the N- or at the C-terminal end. Can J Physiol Pharmacol 1979;57:1018-23
   PubMed Web of Science ®Google Scholar
• McEachern AE, Shelton ER, Bhakta S, Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 1991;88:7724-8
   PubMed Web of Science ®Google Scholar
• Menke JG, Borkowski JA, Bierilo KK, Expression cloning of a human B1 bradykinin receptor. J Biol Chem 1994;269:21583-6
   PubMed Web of Science ®Google Scholar
• Blaukat A, Herzer K, Schroeder C, Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation. Biochemistry 1999;38:1300-9
   PubMed Web of Science ®Google Scholar
• Enquist J, Skröder C, Whistler JL, Leeb-Lundberg FLM. Kinins promote B2 receptor endocytosis and delay B1 receptor endocytosis. Mol Pharmacol 2007;71:494-507
   PubMed Web of Science ®Google Scholar
• Linz W, Wiemer G, Gohlke P, Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49
   PubMed Web of Science ®Google Scholar
• Ehrenfeld P, Millan C, Matus E, Activation of kinin B1 receptors induces chemotaxis of human neutrophils. J Leukoc Biol 2006;80:117-24
   PubMed Web of Science ®Google Scholar
• Ehrenfeld P, Matus CE, Pavicic F, Kinin B1 receptor activation turns on exocytosis of matrix metalloprotease-9 and myeloperoxidase in human neutrophils: involvement of mitogen-activated protein kinase family. J Leukoc Biol 2009;86:1179-89
   PubMed Web of Science ®Google Scholar
• Niggli V. Signaling to migration in neutrophils: importance of localized pathways. Int J Biochem Cell Biol 2003;35:1619-38
   PubMed Web of Science ®Google Scholar
• Williams RJ, Henderson LM, Naidoo Y, Immunocytochemical analysis of tissue kallikrein and the kinin moiety in rheumatoid synovial fluid neutrophils. Br J Rheumatol 1997;36:420-5
   PubMedGoogle Scholar
• Cassim B, Shaw OM, Mazur M, Kallikreins, kininogens and kinin receptors on circulating and synovial fluid neutrophils: role in kinin generation in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:490-6
   PubMed Web of Science ®Google Scholar
• Linz W, Schölkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992;20(Suppl 9):S83-90
   PubMedGoogle Scholar
• Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 2004;90:291-8
   Web of Science ®Google Scholar
• Cervenka L, Harrison-Bernard LM, Dipp S, Early onset salt-sensitive hypertension in bradykinin B2 receptor null mice. Hypertension 1999;34:176-80
   PubMed Web of Science ®Google Scholar
• Majima M, Hayashi I, Fujita T, Facilitation of renal kallikrein-kinin system prevents the development of hypertension by inhibition of sodium retention. Int Immunopharmacol 1999;44:145-52
   PubMedGoogle Scholar
• Meneton P, Bloch-Faure M, Hagege AA, Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 2001;98:2634-9
   PubMed Web of Science ®Google Scholar
• Marceau F, Hess JF, Bachvarov DR. The B1 receptor for kinins. Pharmacol Rev 1998;50:357-86
   PubMed Web of Science ®Google Scholar
• Ni A, Yin H, Agata J, Overexpression of kinin B1 receptors induces hypertensive response to Des-Arg9-bradykinin and susceptibility to inflammation. J Biol Chem 2003;278:219-25
   PubMed Web of Science ®Google Scholar
• Duka I, Kintsurashvili E, Gavras I, Vasoactive potential of the B1 bradykinin receptor in normotension and hypertension. Circ Res 2001;88:275-81
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Murakami H, Ura N, Renal protective role of bradykinin B1 receptor in stroke-prone spontaneously hypertensive rats. Hypertens Res 2004;27:399-408
   PubMed Web of Science ®Google Scholar
• Emanueli C, Minasi A, Zacheo A, Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 2001;103:125-32
   PubMed Web of Science ®Google Scholar
• Miura S, Matsuo M, Saku S. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 2003;41:1118-23
   PubMed Web of Science ®Google Scholar
• Emanueli C, Salis MB, van Linthout S, Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 2004;110:1638-44
   PubMed Web of Science ®Google Scholar
• Innis RB, Manning DC, Stewart JM. Snyder SH. [3H]bradykinin receptor binding in mammalian tissue membranes. Proc Natl Acad Sci USA 1981;78:2630-4
   PubMed Web of Science ®Google Scholar
• Figueroa CD, Müller-Esterl W. Autoradiographic and immunological techniques to analyse kinin receptor distribution in rat and human tissues. Biol Res 1998;31:175-87
   PubMed Web of Science ®Google Scholar
• Murone C, Perich RB, Schlawe I, Characterization and localization of bradykinin B2 receptors in the guinea-pig using a radioiodinated HOE140 analogue. Eur J Pharmacol 1996;306:237-47
   PubMed Web of Science ®Google Scholar
• Murone C, Paxinos G, Mckinley MJ, Distribution of bradykinin B2 receptors in sheep brain and spinal cord visualized by in vitro autoradiography. J Comp Neurol 1997;381:203-18
   PubMed Web of Science ®Google Scholar
• Campos MM, Ongali B, De Souza Buck H, Expression and distribution of kinin B1 receptor in the rat brain and alterations induced by diabetes in the model of streptozotocin. Synapse 2005;57:29-37
   PubMed Web of Science ®Google Scholar
• Schremmer-Danninger E, Offner A, Siebeck M, Autoradiographic visualization of B1 bradykinin receptors in porcine vascular tissues in the presence or absence of inflammation. Int Immunopharmacol 1996;33:95-100
   Google Scholar
• Wu J, Akaike T, Hayashida K, Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002;98:29-35
   PubMed Web of Science ®Google Scholar
• Molina L, Matus CE, Astroza A, Stimulation of the bradykinin B1 receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK1/2 signaling pathway. Breast Cancer Res Treat 2009;118:499-510
   PubMed Web of Science ®Google Scholar
• Vio CP, Velarde V, Müller-Esterl W. Cellular distribution and fate of the bradykinin antagonist HOE140 in the rat kidney. Colocalization with the bradykinin B2 receptor. Int Immunopharmacol 1996;33:146-50
   Google Scholar
• El-Dahr SS, Figueroa CD, Gonzalez CB, Müller-Esterl W. Ontogeny of bradykinin B2 receptors in the rat kidney: Implications for segmental nephron maturation. Kidney Int 1997;51:739-49
   PubMed Web of Science ®Google Scholar
• Ehrenfeld P, Conejeros I, Pavicic MF, Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells. Cancer Lett 2011;301:106-18
   PubMed Web of Science ®Google Scholar
• Figueroa CD, Gonzalez CB, Grigoriev S, Probing for the bradykinin B2 receptor in the rat kidney by anti-peptide and anti-ligand antibodies. J Histochem Cytochem 1995;43:137-48
   PubMed Web of Science ®Google Scholar
• Hess JF, Borkowski JA, Young GS, Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 1992;184:260-8
   PubMed Web of Science ®Google Scholar
• Figueroa CD, Marchant A, Novoa U, Differential distribution of bradykinin B2 receptors in the rat and human cardiovascular system. Hypertension 2001;37:110-20
   PubMed Web of Science ®Google Scholar
• Haasemann M, Cartaud J, Müller-Esterl W, Dunia I. Agonist-induced redistribution of bradykinin B2 receptor in caveolae. J Cell Sci 1998;111:917-28
   PubMed Web of Science ®Google Scholar
• Marin Castaño ME, Praddaude F, Bompart G, RT-PCR microlocalization of bradykinin B2 receptor mRNA in microdissected rat nephron segments. Int Immunopharmacol 1996;33:171-3
   Google Scholar
• Hess JF, Derrick AW, MacNeil T, Borkowski JA. The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors. Int Immunopharmacol 1996;33:1-8
   Google Scholar
• Schanstra JP, Bataillé E, Marin Castaño ME, The B1 agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest 1998;101:2080-91
   PubMed Web of Science ®Google Scholar
• Matus CE, Ehrenfeld P, Pavicic F, Activation of kinin B1 receptor triggers differentiation of cultured human keratinocytes. Br J Dermatol 2008;159:792-803
   PubMed Web of Science ®Google Scholar
• Dlamini Z, Bhoola KD. Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J Clin Pathol 2005;58:915-22
   PubMed Web of Science ®Google Scholar
• Chee J, Naran A, Misso NL, Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol Chem 2008;389:1225-33
   PubMed Web of Science ®Google Scholar
• Taub JS, Guo R, Leeb-Lundberg LM, Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 2003;63:2037-41
   PubMed Web of Science ®Google Scholar
• Wong J, Sia YY, Misso NL, Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura. Pathol Res Int 2011:167046
   PubMedGoogle Scholar
• Bawolak MT, Gera L, Morissette G, Fluorescent ligands of the bradykinin B1 receptors: Pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression. J Pharmacol Exp Ther 2009;329:159-68
   PubMed Web of Science ®Google Scholar
• Bawolak MT, Gera L, Bouthillier J, A fluorescent version of the bradykinin B2 receptor antagonist B-9430: Pharmacological characterization and use in live cell imaging. Peptides 2008;29:1626-30
   PubMed Web of Science ®Google Scholar
• Gera L, Bawolak MT. Caroline Roy, et al. Design of fluorescent bradykinin analogs: Application to imaging of B2 receptor-mediated agonist endocytosis and trafficking and angiotensin-converting enzyme. J Pharmacol Exp Ther 2011;337:33-41
   PubMed Web of Science ®Google Scholar
• Gera L, Roy C, Bawolak MT, N-terminal extended conjugates of the agonists and antagonists of both bradykinin receptor subtypes: structure-activity relationship, cell imaging using ligands conjugated with fluorophores and prospect for functionally active cargoes. Peptides 2012;34:433-46
   PubMed Web of Science ®Google Scholar
• Stewart JM. Bradykinin antagonists. Discovery and development. Peptides 2004;25:527–32
   PubMed Web of Science ®Google Scholar
• Schachter M, Uchida Y, Longridge DJ, . New synthetic antagonists of bradykinin. Br J Pharmacol 1987;92:851–5
   PubMed Web of Science ®Google Scholar
• Whalley ET, Clegg S, Stewart JM, Vavrek RJ. The effect of kinin agonists and antagonists on the pain response of the human blister base. Naunyn Schmiedebergs Arch Pharmacol 1987;336:652–5
   PubMed Web of Science ®Google Scholar
• Schröder E. Structure-Activity relationships of kinins. In: Erdos EG, editor. Handbook of experimental pharmacology, bradykinin, kallidin and kallikrein. Volume 25 Springer-Verlag-Berlin; Heidelberg: 1970. p. 324-50
   Google Scholar
• Nicolaides ED, DeWald HA, Craft MK. The synthesis of kinin analogues. Ann NY Acad Sci 1963;104:15-23
   PubMed Web of Science ®Google Scholar
• Stewart J. Chemistry and biological activity of peptides related to bradykinin. In: Erdos EG, editor. Handbook of experimental pharmacology, supplement; bradykinin, kallidin and kallikrein. Volume 25 Springer-Verlag-Berlin; Heidelberg: 1979. p. 227-72
   Google Scholar
• Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:1-46
   PubMed Web of Science ®Google Scholar
• Wirth K, Breipohl G, Stechl J, DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe 140]) is a potent bradykinin B1 receptor antagonist. Eur J Pharmacol 1991;205:217-18
   PubMed Web of Science ®Google Scholar
• Stewart JM, Gera L, Hanson W, A new generation of bradykinin antagonists. Immunopharmacology 1996;33:51-60
   PubMed Web of Science ®Google Scholar
• Hock FJ, Wirth K, Albus U, . Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102:769–73
   PubMed Web of Science ®Google Scholar
• Charignon D, Spath L, Martin L, Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin Pharmacother 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cheronis JC, Whalley ET, Nguyen KT, A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem 1992;35:1563-72
   PubMed Web of Science ®Google Scholar
• Rodell TC. The kallikrein/kinin system and kinin antagonists in trauma. Immunopharmacology 1996;332:79-83
   Google Scholar
• Gera L, Stewart JM. A new class of bradykinin antagonists containing indanylglycine. Immunopharmacology 1996;33:174-7
   PubMedGoogle Scholar
• Gera L, Stewart JM, Whalley E, A new class of potent bradykinin antagonist dimers. Immunopharmacology 1996;33:178-82
   PubMedGoogle Scholar
• Chan D, Gera L, Stewart J, Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc Natl Acad Sci USA 2002;99:4608-13
   PubMed Web of Science ®Google Scholar
• Wong CT, Rowlands DK, Wong CH, Orally active peptidic bradykinin b(1) receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew Chem Int Ed Engl 2012;51:5620-4
   PubMed Web of Science ®Google Scholar
• Dziadulewicz EK. Non-peptide ligands for bradykinin receptors 1995 – 2004. Expert Opin Ther Patents 2005;15:829-59
   Web of Science ®Google Scholar
• Fincham CI, Bressan A, Paris M, Bradykinin receptor antagonists–a review of the patent literature 2005 – 2008. Expert Opin Ther Patents 2009;19:919-41
   PubMed Web of Science ®Google Scholar
• Aramori I, Zenkoh J, Morikawa N, Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol Pharmacol 1997;51:171-6
   PubMed Web of Science ®Google Scholar
• Asano M, Inamura N, Hatori C, Discovery of orally active nonpeptide bradykinin B2 receptor antagonists. Immunopharmacology 1999;43:163-8
   PubMedGoogle Scholar
• Narotam PK, Rodell TC, Nadvi SS, Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir (Wien) 1998;140(8):793-802
   PubMed Web of Science ®Google Scholar
• Marmarou A, Nichols J, Burgess J, Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J Neurotrauma 1999;16:431-44
   PubMed Web of Science ®Google Scholar
• Pruneau D, Paquet JL, Luccarini JM, Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology 1999;43:187-94
   PubMedGoogle Scholar
• Pruneau D, Chorny I, Benkovitz V, Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma. J Neurotrauma 1999;16:1057-65
   PubMed Web of Science ®Google Scholar
• Zweckberger K, Plesnila N. Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. Neurosci Lett 2009;454(2):115-17
   PubMed Web of Science ®Google Scholar
• Burgess GM, Perkins MN, Rang HP, . Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 2000;129:77–86
   PubMed Web of Science ®Google Scholar
• Valenti C, Cialdai C, Giuliani S, MEN16132, a novel potent and selective nonpeptide kinin B2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs. J Pharmacol Exp Ther 2005;315:616-23
   PubMed Web of Science ®Google Scholar
• Gera L, Chan DC, Helfrich B, Bradykinin related compounds having anti-cancer activity in vivo superior to cisplatin and SU5416. In: Martinez J, Fehrentz J-A, editors. Peptides 2000 (Proceedings of the 26th European Peptide Symposium); Montpellier, EDK, Paris; 2001. p. 637-8
   Google Scholar
• Fincham CI, Bressan A, D'Andrea P, Design and synthesis of novel sulfonamide-containing bradykinin hB(2) receptor antagonists. Synthesis and structure-relationships of α,α-tetrahydropyranylglycine. Bioorg Med Chem 2012;20:2091-100
   PubMed Web of Science ®Google Scholar
• Perkins MN, Campbell E, Dray A. Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des-Arg9, [Leu8]-BK and HOE 140, in two models of persistent hyperalgesia in the rat. Pain 1993;53:191-7
   PubMed Web of Science ®Google Scholar
• Porreca F, Vanderah TW, Guo W, Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist. J Pharmacol Exp Ther 2006;318:195-205
   PubMed Web of Science ®Google Scholar
• Meotti FC, Campos R, da Silva K, Inflammatory muscle pain is dependent on the activation of kinin B1 and B2 receptors and intracellular kinase pathways. Br J Pharmacol 2012;166:1127-39
   PubMed Web of Science ®Google Scholar
• Gougat J, Ferrari B, Sarran L, SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004;309:661-9
   PubMed Web of Science ®Google Scholar
• Fox A, Kaur S, Li B, Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor. Br J Pharmacol 2005;144:889-99
   PubMed Web of Science ®Google Scholar
• Kuduk SD, Di Marco CN, Chang RK, Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists. J Med Chem 2007;50:272-82
   PubMed Web of Science ®Google Scholar
• Hawkinson JE, Szoke BG, Garofalo AW, Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. J Pharmacol Exp Ther 2007;322:619-30
   PubMed Web of Science ®Google Scholar
• Barth M, Bondoux M, Luccarini JM, From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists. J Med Chem 2012;55:2574-84
   PubMed Web of Science ®Google Scholar
• Marceau F, deBlois D, Petitclerc E, Vascular smooth muscle contractility assays for inflammatory and immunological mediators. Int Immunopharmacol 2010;10:1344-53
   PubMed Web of Science ®Google Scholar
• Wieczorek M, Pilyavskaya A, Burkard M, Bradykinin antagonists in human systems: correlation between receptor binding, calcium signalling in isolated cells, and functional activity in isolated ileum. Biochem Pharmacol 1997;54:283-91
   PubMed Web of Science ®Google Scholar
• Guevara-Lora I. Kinin-mediated inflammation in neurodegenerative disorders. Neurochem Int 2012;61:72-8
   PubMed Web of Science ®Google Scholar
• Relton JK, Becky G, Whalley ET. Kinins and CNS injury and inflammation. Effect of the bradykinin antagonist CP 0597 in animal models of stroke. In: Ruffolo RR Jr, Metcalf B, Poste G, editors. Inflammatory cells and mediators in CNS diseases. Harwood Academic Publishers; London: 1998. p. 359-76
   Google Scholar
• Su J, Cui M, Tang Y, Blockade of bradykinin B2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition. Biochem Biophys Res Commun 2009;388:205-11
   PubMed Web of Science ®Google Scholar
• Raslan F, Schwarz T, Meuth SG, Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J Cereb Blood Flow Metab 2010;30:1477-86
   PubMed Web of Science ®Google Scholar
• Albert-Weissenberger C, Stetter C, Meuth SG, Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation. J Cereb Blood Flow Metab 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Austinat M, Braeuninger S, Pesquero JB, Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 2009;40:285-93
   PubMed Web of Science ®Google Scholar
• Trabold R, Erös C, Zweckberger K, The role of bradykinin B1 and B2 receptors for secondary brain damage after traumatic brain injury in mice. J Cereb Blood Flow Metab 2010;30:130-9
   PubMed Web of Science ®Google Scholar
• Göbel K, Pankratz S, Schneider-Hohendorf T, Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun 2011;36:106-14
   PubMed Web of Science ®Google Scholar
• Dutra RC, Leite DF, Bento AF, The role of kinin receptors in preventing neuroinflammation and its clinical severity during experimental autoimmune encephalomyelitis in mice. PLoS One 2011;6:e27875
   PubMed Web of Science ®Google Scholar
• Schulze-Topphoff U, Prat A, Prozorovski T, Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 2009;15:788-93
   PubMed Web of Science ®Google Scholar
• Wilson DD, de Garavilla L, Kuhn W, D-Arg-[Hyp3-D-Phe7]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock. Circ Shock 1989;27:93-101
   PubMedGoogle Scholar
• Ridings PC, Sugerman HJ, Blocher CR, Hemodynamic effects of bradykinin antagonism in porcine gram-negative sepsis. J Invest Surg 1995;8:115-22
   PubMed Web of Science ®Google Scholar
• Siebeck M, Spannagl E, Schorr M, Effect of combined B1 and B2 kinin receptor blockade in porcine endotoxin shock. Immunopharmacology 1996;33:81-4
   PubMedGoogle Scholar
• Félétou M, Jamonneau I, Germain M, Bradykinin B2 receptor involvement in rabbit and murine models of septic shock. J Cardiovasc Pharmacol 1996;27:500-7
   PubMed Web of Science ®Google Scholar
• Barratt-Due A, Johansen HT, Sokolov A, The role of bradykinin and the effect of the bradykinin receptor antagonist icatibant in porcine sepsis. Shock 2011;36:517-23
   PubMed Web of Science ®Google Scholar
• Cayla C, Todiras M, Iliescu R, Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 2007;21:1689-98
   PubMed Web of Science ®Google Scholar
• Klein, J, Gonzalez J, Duchene J, et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 2009;23:134-42
   PubMed Web of Science ®Google Scholar
• Pereira RL, Buscariollo BN, Correa-Costa M, Bradykinin receptor 1 activation exacerbates experimental focal and segmental glomerulosclerosis. Kidney Int 2011;79:1217-27
   PubMed Web of Science ®Google Scholar
• Wang PHM, Campanholle G, Cenedeze MA, Bradykinin B1 receptor antagonism is beneficial in renal ischemia-reperfusion injury. PLoS One 2008;3:e3050
   PubMed Web of Science ®Google Scholar
• Kakoki M, McGarrah RW, Kim HS, Smithies O. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2007;104:7576-81
   PubMed Web of Science ®Google Scholar
• Morissette G, Houle S, Gera L, Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br J Pharmacol 2007;150:369-79
   PubMed Web of Science ®Google Scholar
• Available from: www.apoplogic.com
   Google Scholar
• Austin CE, Foreman JC, Scadding GK. Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. Br J Pharmacol 1994;111:969-71
   PubMed Web of Science ®Google Scholar
• Turner P, Dear J, Scadding G, Foreman JC. Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J Allergy Clin Immunol 2001;107:105-13
   PubMed Web of Science ®Google Scholar
• Akbary AM, Wirth KJ, Schölkens BA. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 1996;33:238-42
   PubMed Web of Science ®Google Scholar
• Shakur H, Andrews P, Asser T, I. The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 2009;10:109-18
   PubMed Web of Science ®Google Scholar
• Cockcroft JR, Chowienczyk PJ, Brett SE, Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 1994;38:317-21
   PubMed Web of Science ®Google Scholar
• Gao BB, Clermont A, Rook S, Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007;13:181-8
   PubMed Web of Science ®Google Scholar
• Huang H, Player MR. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. J Med Chem 2010;53(15):5383-99
   PubMed Web of Science ®Google Scholar
• Cicardi M, Banerji A, Bracho F, Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41
   PubMed Web of Science ®Google Scholar
• Fein AM, Bernard GR, Criner GJ, Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997;277:482-7
   PubMed Web of Science ®Google Scholar
• Fuchs K, Fischer K, Schwenck J, In vivo PET imaging of Bradykinin Receptor 1 (B1R) expression in a mouse model of chronic inflammation [Presentation Number T103]. World Molecular Imaging Congress (WMIC); 7 – 10 September 2011; San Diego, USA; 2011
   Google Scholar